Therapeutic effects and long-term outcomes of HMGB1-targeted therapy in rats and mice with traumatic spinal cord injury: A systematic review and meta-analysis

This study investigates therapeutic methods to prevent traumatic spinal cord injury (TSCI) progression and improve functional recovery. High mobility group box-1 (HMGB1) is released by necrotic neurons or secreted by glial cells after TSCI and plays an important role in pathophysiology. The purpose of this study was to evaluate the effects of HMGB1-targeted therapy on locomotor function recovery, inflammation reduction, edema attenuation, and apoptosis reduction in rat and mouse models of TSCI. The study reviewed literature on HMGB1-targeted therapy in the treatment and prognosis of TSCI, analyzing twelve articles from online databases based on PRISMA guidelines and strict inclusion criteria.

• 1
  HMGB1-targeted therapy improves locomotor function, reduces inflammation, attenuates edema, and reduces apoptosis in rats and mice with TSCI.
• 2
  Intrathecal injection of anti-HMGB1 Ab 0-3 h after SCI may be the most efficacious treatment.
• 3
  Compared with the SCI group, HMGB1 expression was significantly diminished, TNF-α levels were significantly reduced, water content was significantly reduced, and the number of apoptotic cells was significantly diminished in the spinal cord of the treatment group.